PJC 58.47 Piper Jaffray Companies $PJC Hit a 52 week high

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 1:22 PM

PJC 58.47 Piper Jaffray Companies $PJC Hit a 52 week high of 58.84 Closing the day 09:38 at 58.47 -0.50 -0.85% With a day low of 58.58 and a total volume of 3,027.

PJC Recent Posts: http://investorshangout.com/Piper-Jaffray-Com...PJC-52303/

PJC Piper Jaffray Companies Recent Headline News

Insider Trading Alert - PJC, SMCI And ARE Traded By Insiders
at The Street - Tue Nov 11, 10:30AM CST
Stocks with insider trader activity include PJC, SMCI and ARE
SMCI: 34.28 (+0.61), ARE: 83.19 (+0.44), PJC: 57.75 (-1.22)

Piper Jaffray Up 13.6% Since SmarTrend Uptrend Call (PJC)
Comtex SmarTrend(R) - Tue Nov 11, 9:25AM CST
SmarTrend identified an Uptrend for Piper Jaffray (NYSE

JC) on October 23rd, 2014 at $51.93. In approximately 3 weeks, Piper Jaffray has returned 13.61% as of today's recent price of $59.00.
PJC: 57.75 (-1.22)

Investment Technology Group (ITG) Jumps: Stock Rises 7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:32AM CST
Investment Technology Group Inc. (ITG) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
ITG: 19.59 (unch), PJC: 57.75 (-1.22), AI: 27.22 (-0.14), BGCP: 8.53 (-0.12)

Piper Jaffray Companies' (PJC) CEO Andrew Duff on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 23, 3:10PM CDT

PJC: 57.75 (-1.22)

NYSE stocks posting largest percentage increases
AP - Thu Oct 23, 12:52PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at 1 p.m.:
CRS: 51.79 (-0.20), UFS: 41.74 (+0.12), CLV: 10.18 (-0.16), BBW: 18.15 (-0.08), PJC: 57.75 (-1.22), CLF: 10.50 (-0.21), MTRN: 37.84 (-0.82), XRS: 32.23 (+0.02), GPI: 87.79 (-0.59), BRP: 23.52 (+0.01), UIS: 27.33 (-0.57), SIX: 40.57 (-0.30), DF: 16.63 (-0.15)

Piper Jaffray beats by $0.46, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 7:04AM CDT

PJC: 57.75 (-1.22)

Piper Jaffray Companies Announces 2014 Third Quarter Results
Business Wire - Thu Oct 23, 7:03AM CDT
Piper Jaffray Companies (NYSE: PJC) today announced its financial results for the quarter ended September 30, 2014.
PJC: 57.75 (-1.22)

Piper Jaffray Companies to Hold Management Conference Call to Discuss 2014 Third Quarter Results
Business Wire - Wed Oct 15, 11:14AM CDT
Piper Jaffray (NYSE

JC) announced today that it will release its 2014 third quarter results prior to the opening of the market on Thursday, October 23, 2014. The company will also hold a conference call to review the financial results at 9:00 a.m. ET (8:00 a.m. CT). Andrew S. Duff, chairman and chief executive officer, and Debbra L. Schoneman, chief financial officer, will host the call.
PJC: 57.75 (-1.22)

Can Schwab Beat Wall St. For 5 Quarters In A Row?
at Investor's Business Daily - Mon Oct 13, 3:12PM CDT
Recent market choppiness has swamped Charles Schwab along with other brokers. With the waters muddied, it's not clear whether Schwab's earnings will be strong enough to meet or beat Wall Street expectations. The discount broker reports third-quarter...
RJF: 56.77 (-0.28), PJC: 57.75 (-1.22), AMP: 129.96 (-0.32), SCHW: 28.73 (-0.05)

Different is the New Cool, According to Piper Jaffray Survey of 7,200 Teens
Business Wire - Wed Oct 08, 10:00AM CDT
Piper Jaffray (NYSE: PJC) has completed its 28th semi-annual Taking Stock With Teens market research project, which indicates increased spending across categories despite decreased optimism about the economy.
PJC: 57.75 (-1.22)

Uptrend Call Working As Piper Jaffray Stock Rises 23.0% (PJC)
Comtex SmarTrend(R) - Thu Sep 25, 4:43PM CDT
SmarTrend identified an Uptrend for Piper Jaffray (NYSE

JC) on April 25th, 2014 at $44.54. In approximately 5 months, Piper Jaffray has returned 22.96% as of today's recent price of $54.76.
PJC: 57.75 (-1.22)

Piper Jaffray Hits 52-Week High on Capital Market Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 1:58PM CDT
Shares of Piper Jaffray Companies (PJC) crafted a new 52-week high, touching $56.40 on Sep 17.
MRCC: 13.98 (-0.06), PJC: 57.75 (-1.22), AI: 27.22 (-0.14), MC: 34.66 (+0.32)

Piper Jaffray Shares Up 27.0% Since SmarTrend's Buy Recommendation (PJC)
Comtex SmarTrend(R) - Thu Sep 18, 11:04AM CDT
SmarTrend identified an Uptrend for Piper Jaffray (NYSE

JC) on April 25th, 2014 at $44.54. In approximately 5 months, Piper Jaffray has returned 26.96% as of today's recent price of $56.54.
PJC: 57.75 (-1.22)

Schwab's August DATs Witness Marginal Y/Y Decline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 4:50PM CDT
Schwab (SCHW) recorded Daily Average Trades of 460,000 for Aug 2014, reflecting a decline of 1% from the prior-year month and remaining same as that of the prior month.
PJC: 57.75 (-1.22), AI: 27.22 (-0.14), MC: 34.66 (+0.32), SCHW: 28.73 (-0.05)

CIT Group Grows Inorganically: Right Time to Buy the Stock? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 10:40AM CDT
CIT Group Inc. (CIT) has come a long way since its emergence from bankruptcy in 2009. The company is presently focused on growing inorganically.
PJC: 57.75 (-1.22), AI: 27.22 (-0.14), MC: 34.66 (+0.32), CIT: 49.27 (-0.17)

E*TRADE Financial (ETFC) August DARTs Descend 5% Q/Q - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 9:40AM CDT
Online brokerage firm, E*TRADE Financial Corporation (ETFC) reported a decline in its Daily Average Revenue Trades (DARTs) for Aug 2014.
PJC: 57.75 (-1.22), ETFC: 22.89 (+0.06), AMTD: 34.86 (-0.14), SCHW: 28.73 (-0.05)

How Will Visa (V) Stock Respond To These Coverage Initiations?
at The Street - Tue Sep 16, 7:44AM CDT
Visa (V) stock is up in pre-market trade after the financial company had coverage initiated at Sterne Agee, Bernstein and Piper Jaffray (PJC).
V: 251.16 (-0.79), PJC: 57.75 (-1.22)

Morgan Stanley to Phase Out Managed Mutual Fund Platform - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:50PM CDT
Morgan Stanley (MS), the world's largest seller of managed accounts, is phasing out a managed mutual fund program.
PJC: 57.75 (-1.22), AI: 27.22 (-0.14), BAC: 17.15 (-0.14), MS: 35.72 (-0.25)

Capital One's Expenses on Downward Trail, Revenues Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 5:25PM CDT
Capital One exhibits prudent expense management and remains strong in its Credit Card business. However, slump in overall revenues remains a major concern.
COF: 81.45 (-0.12), PJC: 57.75 (-1.22), HSBC: 50.06 (-0.16), AI: 27.22 (-0.14)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Community in Shock After Fatal Bakersfield Shooting

The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...

ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Fluence Energy Hits Legal Snag: Investors Called to Act

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...